• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Vaccinex Inc. (Amendment)

    2/7/24 6:55:18 PM ET
    $VCNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VCNX alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

    Amendment No. 1

    Under the Securities Exchange Act of 1934

     

      Vaccinex, Inc.  
      (Name of Issuer)  
         
      Common Stock, $0.0001 par value per share  
      (Title of Class of Securities)  
         
      918640202  
      (CUSIP Number)  
         
      December 31, 2023  
      (Date of Event Which Requires Filing of this Statement)  
         

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed

     

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

     

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 918640202

     

    1.

    Names of Reporting Persons. AIGH Capital Management, LLC

    I.R.S. Identification Nos. of above persons (entities only).

     

    27-4413262

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ☐

    (b) ☒

    3.

    SEC Use Only

     

    4.

    Citizenship of Place of Organization

     

    Maryland

    Number of Shares Beneficially Owned by Each Reporting Person With 5.

    Sole Voting Power

     

    817,061

    6.

    Shared Voting Power

     

     

    7.

    Sole Dispositive Power

     

    1,247,0611

    8.

    Shared Dispositive Power

     

     

    9.

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    1,247,0611

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐

     

     

    11.

    Percent of Class Represented by Amount in Row 9

     

    9.9%

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    1.

    Includes 430,000 warrants to purchase common stock and excludes 4,570,000 warrants to purchase common stock not currently exercisable due to beneficial ownership limitations on exercise.

     

     

     

     

    CUSIP No. 918640202

     

    1.

    Names of Reporting Persons. AIGH Investment Partners, L.L.C.

    I.R.S. Identification Nos. of above persons (entities only).

     

     

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ☐

    (b) ☒

    3.

    SEC Use Only

     

    4.

    Citizenship of Place of Organization

     

    Delaware

    Number of Shares Beneficially Owned by Each Reporting Person With 5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

     

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

     

    9.

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    0

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐

     

     

    11.

    Percent of Class Represented by Amount in Row 9

     

    0%

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

     
     

     

    CUSIP No. 918640202

     

    1.

    Names of Reporting Persons. Orin Hirschman

    I.R.S. Identification Nos. of above persons (entities only).

     

     

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ☐

    (b) ☒

    3.

    SEC Use Only

     

    4.

    Citizenship of Place of Organization

     

    United States

    Number of Shares Beneficially Owned by Each Reporting Person With 5.

    Sole Voting Power

     

    817,061

    6.

    Shared Voting Power

     

     

    7.

    Sole Dispositive Power

     

    1,247,0611

    8.

    Shared Dispositive Power

     

     

    9.

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    1,247,0611

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐

     

     

    11.

    Percent of Class Represented by Amount in Row 9

     

    9.9%

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

      1. Includes 430,000 warrants to purchase common stock and excludes 4,570,000 warrants to purchase common stock not currently exercisable due to beneficial ownership limitations on exercise.

     

     

     

     

    ITEM 1:

     

    (a) Name of Issuer:

     

    Vaccinex, Inc.

     

    (b) Address of Issuer’s Principal Executive Offices:

     

    1895 Mount Hope Avenue

    Rochester, NY 14620

     

    ITEM 2:

     

    (a) Name of Person Filing:

     

    This Schedule 13G is being jointly filed by each of the following persons pursuant to Rule 13d-1 promulgated by the Securities and Exchange Commission pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the “Act”):

     

      (i) AIGH Capital Management, LLC, a Maryland limited liability company (“AIGH CM”), as an Advisor or Sub-Advisor with respect to shares of Common Stock (as defined in Item 2(d) below) held by AIGH Investment Partners, L.P., WVP Emerging Manger Onshore Fund, LLC – AIGH Series, and WVP Emerging Manger Onshore Fund, LLC- Optimized Equity Series;

     

      (ii)

    AIGH Investment Partners, L.L.C., a Delaware limited liability company (“AIGH LLC”), with respect to shares of Common Stock (as defined in Item 2(d) below) directly held by it;

         
      (iii) Mr. Orin Hirschman (“Mr. Hirschman”), who is the Managing Member of AIGH Capital Management, LLC and president of AIGH LLC, with respect to shares of Common Stock (as defined in Item 2(d) below) indirectly held through AIGH CM, directly by AIGH LLC and Mr. Hirschman and his family directly.

     

    AIGH Capital Management LLC., AIGH Investment Partners LLC, and Mr. Hirschman are hereinafter sometimes collectively referred to as the “Reporting Persons.” Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

     

    (b) Address of Principal Business Office or, if None, Residence:

     

    The principal office and business address of AIGH Capital Management LLC, AIGH Investment Partners LLC, and Mr. Hirschman is:

     

    6006 Berkeley Avenue

    Baltimore MD 21209

     

    (c) Citizenship:

     

    See Item 2(a) above and Item 4 of each cover page.

     

    (d) Title of Class of Securities:

     

    Common Stock, $0.0001 par value per share

     

    (e) CUSIP Number:

     

    918640202

     

     

     

     

    ITEM 3: IF THIS STATEMENT IS FILED PURSUANT TO §§240.13D-1(B) OR 240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
           
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
           
      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
           
      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
           
      (e) ☒ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ☐ A non-U.S. institution, in accordance with §240.13d-1(b)(1)(ii)(J);
           
      (k) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K).
           
         

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ___________________________.

     

    ITEM 4: OWNERSHIP.

     

    See Item s 5,6,7,8 and 9 of each cover page.

     

    ITEM 5: OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐

     

    ITEM 6: OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

     

    Not applicable.

     

    ITEM 7: IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

     

    Not applicable.

     

    ITEM 8: IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

     

    Not applicable.

     

    ITEM 9: NOTICE OF DISSOLUTION OF GROUP.

     

    Not applicable.

     

    ITEM 10: CERTIFICATIONS.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 7, 2024 By: /s/ Orin Hirschman
        Orin Hirschman,
        Individually and as (a) managing member of AIGH Capital Management LLC.: and (b) president of AIGH Investment Partners LLC.

     

     

     

    Get the next $VCNX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VCNX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VCNX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

      Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in patients with metastatic melanoma. Pepinemab, Semaphorin 4D blocking immunotherapy, also appears to induce the formation of efficient lymphoid structures in "cold" tumors of patients with recurrent and metastatic head and neck cancer. ROCHESTER, N.Y., April 21, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and Alzheimer's disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present exciting ne

      4/21/25 8:45:00 AM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

      ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC:VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced that it has notified the Nasdaq Stock Market ("Nasdaq") of its decision to delist the Company's shares of common stock, par value $0.0001 per share (the "Common Stock"), from Nasdaq. Trading in the Common Stock on Nasdaq has been suspended since December 18, 2024. Vaccinex intends to file a Form 25 with the Securities and Exchange Commission on or about March 17, 2025 to

      3/7/25 5:15:00 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaccinex Announces Receipt of Delisting Notification from Nasdaq

      ROCHESTER, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced that on December 16, 2024, the Company received written notice (the "Notice") from the Office of General Counsel of The Nasdaq Stock Market ("Nasdaq") indicating that the Nasdaq Hearings Panel has determined to delist the Company's shares from Nasdaq due to the Company's failure to meet Nasdaq's continued listing standards. As previously disclosed, the Company has not been

      12/17/24 9:00:00 AM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VCNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Friedberg Albert bought $451 worth of shares (100 units at $4.51) (SEC Form 4)

      4 - VACCINEX, INC. (0001205922) (Issuer)

      8/13/24 4:30:45 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Friedberg Albert bought $30,349 worth of shares (6,406 units at $4.74) (SEC Form 4)

      4 - VACCINEX, INC. (0001205922) (Issuer)

      8/7/24 4:04:52 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Friedberg Albert bought $55,238 worth of shares (11,703 units at $4.72) (SEC Form 4)

      4 - VACCINEX, INC. (0001205922) (Issuer)

      8/2/24 4:05:32 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VCNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Vaccinex Inc.

      SC 13D/A - VACCINEX, INC. (0001205922) (Subject)

      11/18/24 4:15:28 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Vaccinex Inc.

      SC 13G - VACCINEX, INC. (0001205922) (Subject)

      11/14/24 3:39:20 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Vaccinex Inc.

      SC 13D/A - VACCINEX, INC. (0001205922) (Subject)

      9/20/24 5:15:25 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VCNX
    SEC Filings

    See more

    $VCNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 10-K filed by Vaccinex Inc.

      10-K - VACCINEX, INC. (0001205922) (Filer)

      4/15/25 5:12:41 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-K filed by Vaccinex Inc.

      NT 10-K - VACCINEX, INC. (0001205922) (Filer)

      4/1/25 7:01:02 AM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by Vaccinex Inc.

      15-12G - VACCINEX, INC. (0001205922) (Filer)

      3/27/25 8:24:58 AM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Friedberg Albert was granted 30,756 shares (SEC Form 4)

      4 - VACCINEX, INC. (0001205922) (Issuer)

      11/18/24 4:06:19 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Zauderer Maurice was granted 46,153 shares (SEC Form 4)

      4 - VACCINEX, INC. (0001205922) (Issuer)

      11/18/24 4:05:50 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Zauderer Maurice exercised 113,650 shares at a strike of $5.64 (SEC Form 4)

      4 - VACCINEX, INC. (0001205922) (Issuer)

      9/20/24 4:14:02 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care